The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

One of those is Boston-based Syntis Bio, which is working on a daily pill that mimics the effects of gastric bypass—no actual ...

In a small Phase II trial, people with cocaine use disorder who took mavoglurant used the drug less often over a three month ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

This new research confirmed earlier findings showing that the experimental drug — lepodisiran, made by Eli Lilly, who funded the study — can "silence" the main gene responsible for ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...